Literatur
-
1 Tumorzentrum München .Manual Gastrointestinale Tumoren: Empfehlungen zur Diagnostik, Therapie und Nachsorge. 8. Aufl. 2010
-
2
Jemal A. et al .
Cancer statistics, 2008.
CA Cancer J Clin.
2008;
58
71-96
-
3
Schmiegel W. et al .
[Update S3-guideline ”colorectal cancer” 2008].
Z Gastroenterol.
2008;
46
799-840
-
4
Grothey A. et al .
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
J Clin Oncol.
2004;
22
1209-1214
-
5
Harris M.
Monoclonal antibodies as therapeutic agents for cancer.
Lancet Oncol.
2004;
5
292-302
-
6
Veronese M L, O’Dwyer P J.
Monoclonal antibodies in the treatment of colorectal cancer.
Eur J Cancer.
2004;
40
1292-12 301
-
7
Van Cutsem E. et al .
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med.
2009;
360
1408-1417
-
8
Bokemeyer C. et al .
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
J Clin Oncol.
2009;
27
663-671
-
9
Van Cutsem E. et al .
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol.
2007;
25
1658-1664
-
10
Adam R.
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.
Ann Oncol.
2003;
14 (Suppl 2)
ii13-16
-
11
Nordlinger B. et al .
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40 983): a randomised controlled trial.
Lancet.
2008;
371
1007-1016
-
12
Van Cutsem E. et al .
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial.
ASCO Gastrointestinal Cancers Symposium.
2010;
#281
-
13
Bokemeyer C. et al .
Biomarkers predictive for outcome in patients with metastatic colorectal cancer treated with first-line FOLFOX-4 plus or minus cetuximab: Updated data from the OPUS study.
ASCO Gastrointestinal Cancers Symposium.
2010;
#428
-
14
Maughan T. et al .
Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer.
ASCO Gastrointestinal Cancers Symposium.
2010;
#402
-
15
Folprecht G. et al .
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
Ann Oncol.
2005;
16
1311-1319
-
16
Folprecht G. et al .
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Lancet Oncol.
2010;
11
38-47
-
17
Jonker D J. et al .
Cetuximab for the treatment of colorectal cancer.
N Engl J Med.
2007;
357
2040-2048
-
18
Cunningham D. et al .
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
N Engl J Med.
2004;
351
337-345
-
19
Moosmann N, Heinemann V.
Cetuximab in the treatment of metastatic colorectal cancer.
Expert Opin Biol Ther.
2007;
7
243-256
-
20
Andre T. et al .
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
N Engl J Med.
2004;
350
2343-2351
Dr. med. Nicolas Moosmann
Medizinische Klinik III
Klinikum München-Großhadern
Marchioninistraße 15
81377 München
eMail: Nicolas.Moosmann@med.uni-muenchen.de
